| abstract |
Disclosed is a pharmaceutical combination for the treatment of diseases associated with cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. A pharmaceutical combination comprising the following two components. (i) an antagonist of at least one receptor selected from VEGFR1 to 3, PDGFRα and β, FGFR1, 2 and 3, EGFR, HER2, IGF1R, HGFR or c-Kit (this is also an antagonist of the src tyrosine kinase family member) And) (ii) At least a further chemotherapeutic agent or a naturally occurring, semi-synthetic or synthetic therapeutic agent. [Selection figure] None |